Moderna strain surges after release of promising coronavirus vaccine data

modernOn Wednesday, after a biotech company released promising data on a potential clinical trial of the coronavirus vaccine, the company’s stock price soared 12 percent on Wednesday, saying it had created a “robust” immune response.

On Tuesday night in the Neutral Journal of Medicine, scientists in Moderna announced Tuesday that a vaccine candidate had produced neutralizing antibodies. Furthermore, the antibodies produced were higher than those found in those who recovered from Covid-19.

The newly released data “point to a positive path for large phase III trials that want to demonstrate safety and efficacy.”Squark box“

Scientists warned that the Phase 1 study was small, only 45 were all healthy, and the results could be different in other populations, such as those with underlying illnesses. I am.

“We believe there is an ethical obligation to move this vaccine as quickly as possible given the unmet needs on the one hand and the science that we can do on the other hand,” Sachs said. “I think it’s our duty to do this in a responsible and sensible way and to explain a new understanding of the safety profile. We see that Phase 3 is a big Phase 3 I think we do it by ensuring.”

Public health officials say they can’t return to “normal” until there is a vaccine. According to data compiled by Johns Hopkins University, there are no FDA-approved drugs or vaccines for coronaviruses, affecting more than 13 million people worldwide and killing at least 578,600 people as of Wednesday.

Moderna’s vaccine contains genetic material called messenger RNA or mRNA. It wants scientists to provoke the immune system to fight the virus. New data raise expectations that there may be a safe and effective vaccine to prevent Covid-19 by the end of the year or early 2021.

In an early stage study conducted by the National Institutes of Health, Each participant received 25, 100, or 250 micrograms of the vaccine candidate, with 15 participants in each treatment group. Participants were vaccinated twice. The data show no serious side effects, but more than half of participants report mild or moderate symptoms such as injection site fatigue, muscle aches and pain.

Moderna announced Tuesday that it will begin its late-stage trials That vaccine on July 27. According to ClinicalTrials.gov, the trial will enroll 30,000 participants in 87 locations. Participants in the group will receive an additional 100 micrograms of vaccine candidate on Days 1 and 29. Some patients in the trial will also receive placebo

The Moderna effort is one of several working on a potential vaccine for Covid-19. According to the World Health Organization, over 100 vaccines are under development worldwide. According to the WHO, at least 23 people are already in human trial.

Earlier this month, pharmaceutical giants Pfizer BioNTech, a German pharmaceutical company, has published the results of an early human trial with close scrutiny of the coronavirus vaccine. Preliminary data, according to the company, indicate that the vaccine produced neutralizing antibodies in all participants who received two doses of 10 or 30 micrograms after 28 days. The level of neutralizing antibodies was said to be 1.8-2.8 times that of recovered Covid-19 patients.

The results of Moderna and Pfizer are promising, but scientists warn that the response of the human body after being infected by a virus remains questionable. They say the answer could have important implications for vaccine development.

One important question among scientists is whether to prevent the antibodies produced in response to Covid-19 from reinfecting.

Scientists hope the antibody will provide some protection against the acquisition of Covid-19, but it’s still unclear because it’s only six months after the virus was first discovered. Hmm. No detailed studies have been conducted and some patients appear to be reinfected after recovery from Covid-19.

“I think there are many optimisms,” said Dr. Jonathan Abraham, professor of microbiology and immunobiology at Harvard Medical School. “But I think optimism makes a lot of assumptions. What we’re seeing now is a type of infection that, if infected, will be infected and then re-exposed shortly thereafter. It is included.”

further, Recent research Coronavirus antibodies may last only a few months after being infected with Covid-19, according to a publication in Nature Medicine. The researchers investigated 37 asymptomatic people who had never developed symptoms in the Wanzhou District of China. They compared the antibody response with that of 37 symptomatic people.

Dr. Anthony Fauci, the most infectious disease specialist in the United States, is often marketing a potential vaccine for Moderna. He said Monday that a scientist he is “carefully optimistic” can create at least one safe and effective vaccine by the end of the year or the beginning of 2021.

While questions remain, Sachs said Wednesday that scientists learned about the virus from coronavirus-related SARS and MERS. The spike proteins that the virus uses to enter the host cell are an important element in vaccine development, he said.